.jpg)
1 hour ago
4
Article content
- H1 2026 results with sales growth of 23.5% at CER1, or 20.4% as reported, with the portfolio beyond Somatuline® achieving sales growth of 24.8%1 and core operating income of €845m, growing by 28.8% as reported, with a core operating margin of 38.6% of total sales, increasing by 2.5 points
- Upgraded FY 2026 financial guidance2: total sales growth greater than 20.0% at CER (prior guidance: greater than 13.0% at CER); core operating margin greater than 37.0% of total sales (prior guidance: greater than 35.0%)
- Delivering on strategy to accelerate the growth of key medicines and expand the pipeline, adding multiple anticipated near-term launches of assets with blockbuster potential across the three therapeutic areas. Driven by several positive Phase III readouts, for Dysport® in episodic and chronic migraine, Iqirvo® in primary biliary cholangitis and the acquisitions of Kartos Therapeutics3 and Memo Therapeutics AG
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
PARIS, FRANCE, 30 July 2026 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the first half of 2026.
Article content
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
| Extract of consolidated results | H1 2026 | H1 2025 | % change | |
| €m | €m | Actual | TCC | |
| Total Sales | 2 190,2 | 1 819,8 | 20,4 % | 23,5 % |
| Core Operating Income | 844,9 | 655,8 | 28,8 % | |
| Core operating margin | 38,6 % | 36,0 % | +2,5 pts | |
| Core Consolidated Net Profit | 607,7 | 508,3 | 19,6 % | |
| Core earnings per share (fully diluted) | 7,33 € | 6,07 € | 20,7 % | |
| IFRS Operating Income | 564,8 | 451,6 | 25,1 % | |
| IFRS operating margin | 25,8 % | 24,8 % | +1,0 pts | |
| IFRS Consolidated Net Profit | 402,6 | 335,5 | 20,0 % | |
| IFRS earnings per share (fully diluted) | 4,86 € | 4,00 € | 21,4 % | |
| Free Cash Flow | 651,7 | 483,2 | 34,9 % | |
| Closing net cash/(debt) | 1 004,9 | 487,6 | n/a | |
Article content
“Our excellent first-half performance demonstrates the strength of Ipsen’s strategy, with all three therapeutic areas contributing to growth and the portfolio beyond Somatuline continuing to accelerate,” said David Loew, Chief Executive Officer, Ipsen. “This momentum enables us to upgrade our 2026 guidance while continuing to invest in innovation and future growth. Importantly, we have significantly strengthened our late-stage pipeline in the first half, with positive Phase III lifecycle management readouts for Dysport in episodic and chronic migraine and Iqirvo in primary biliary cholangitis, alongside the completed acquisition of Memo Therapeutics AG and the proposed acquisition of Kartos Therapeutics. These transactions add two innovative clinical assets—navtemadlin and potravitug—with the potential to address significant unmet needs and create long-term value. Our expanding pipeline and focused business development strategy further contribute to Ipsen’s sustainable growth outlook and our ability to bring meaningful innovation to patients worldwide.”
Article content
Article content
Full-year 2026 guidance
Article content
Based on the strong performance in the first half, Ipsen upgrades its financial guidance for 2026:
Article content
- Total sales growth greater than 20.0%, at constant currency. Based on the average level of exchange rates in June 2026, an adverse effect on total sales of around 1% of currencies is expected
- Core operating margin greater than 37.0% of total sales, which includes additional R&D expenses from anticipated early and mid-stage external innovation opportunities and assumes the dilutive impact of the acquisitions of Memo Therapeutics AG and Kartos Therapeutics
Article content
Guidance4 on total sales and core operating margin in 2026 is assuming accelerated sales growth of the portfolio excluding Somatuline and the continued growth of Somatuline sales despite potential entry of generic lanreotide.
Article content
Pipeline progress since Q1 2026
Article content
Ipsen presented in May late-breaking Phase II data in Glabellar Lines for corabotase, its first-in-class recombinant neuroinhibitor (RNI™), demonstrating a rapid onset of action, a statistically superior peak effect versus placebo at Week 4 and a clinically significant sustained duration of effect, outperforming both placebo and Dysport at Week 24. Corabotase has been recognized by the WHO (World Health Organization) and USAN (United States Adopted Name) as a novel botase molecule.
English (US)